LCL/LBH suppresses tumor growth in a murine myeloma model. Immunocompetent C57BL/KaLwRij mice were inoculated via the tail vein intravenously with 5 × 10⁶ luciferase-labeled 5TGM1 cells. Mice were randomized to 4 groups (n = 7 or 8 per group). Treatment was initiated after luciferase signal was detected. LCL161 (30 mg/kg, 5 days per week) and LBH (13.3 mg/kg, 3 days per week) were given orally or intraperitoneally, respectively. (A) Tumor growth was monitored every other day after intraperitoneal injection with 100 μL of 15 mg/mL D-luciferin substrate using the PerkinElmer IVIS 200 imaging system. (B) Tumor growth was monitored by whole body imaging and dissection imaging. Arrow, bone marrow lesion (luciferase signals); circle, extramedullary lesion; sp, spleen; 1, cranium; 2, spine; 3/4, scapulars; 5/7, upper limbs; 6/8, lower limbs; 9/10, ilium; 11, brain; 12, lung; 13, liver; 14, stomach; 15/16, kidneys). (C) Tumor growth was quantified by average luciferase activity (photons/second/cm²/sr). P < .05 vs each single treatment (log-rank [Mantel-Cox] test). (D) Kaplan-Meier analysis was conducted to analyze survival. Inset, median survival days. Yellow bar indicate time when treatment (Tx) began (day 13) and was discontinued (day 24). P < .05 vs each single treatment. (E) Body weight was measured every other day. Veh, vehicle.